APLT241220P7500
- 6.58
- +0.08+1.23%
Applied Therapeutics Newsroom
RBC Capital Maintains Applied Therapeutics(APLT.US) With Hold Rating, Cuts Target Price to $1.5
Applied Therapeutics Is Maintained at Sector Perform by RBC Capital
Applied Therapeutics Price Target Cut to $1.50/Share From $4.00 by RBC Capital
Applied Therapeutics Analyst Ratings
Applied Therapeutics CEO Shendelman Steps Down
Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles
Express News | Applied Therapeutics Inc - Funtleyder to Continue as CFO While Serving as Interim CEO
Express News | Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO
Press Release: Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Express News | Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Express News | Applied Therapeutics Inc : RBC Cuts Target Price to $1.5 From $4
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
Express News | Applied Therapeutics Inc - Joel Marcus Resigns From Applied Therapeutics Board
Wolf Popper LLP Announces Investigation on Behalf of Applied Therapeutics, Inc. Investors
(APLT) - Analyzing Applied Therapeutics's Short Interest
William Blair Maintains Applied Therapeutics(APLT.US) With Buy Rating
Buy Rating Maintained for Applied Therapeutics Amidst SORD Program Potential and Regulatory Challenges
Insiders Could Have Profited By Holding Onto Applied Therapeutics Shares Despite 84% Drop
Optimistic Outlook for Applied Therapeutics Despite FDA Setback
Applied Therapeutics Faces FDA Challenges With Govorestat